Review:
Molecular Targeted Therapies For Thyroid Cancer
overall review score: 4.2
⭐⭐⭐⭐⭐
score is between 0 and 5
Molecular-targeted therapies for thyroid cancer represent a class of treatments that focus on specific molecular pathways and genetic mutations involved in the development and progression of thyroid malignancies. These therapies aim to inhibit abnormal signaling pathways, such as those involving angiogenesis, tyrosine kinases, and other oncogenic drivers, thereby providing more precise and potentially more effective treatment options for patients with advanced or radioactive iodine-refractory thyroid cancers.
Key Features
- Target specific molecular pathways like BRAF, RET, and VEGF
- Used primarily for advanced, metastatic, or iodine-resistant thyroid cancers
- Includes drugs such as tyrosine kinase inhibitors (TKIs) like sorafenib, lenvatinib, and vandetanib
- Personalized approach based on genetic profiling of tumors
- Often used in combination with other treatments or as second-line therapies
Pros
- Offers targeted treatment options for difficult-to-treat thyroid cancers
- Potentially improves survival rates and disease management
- Less invasive than traditional chemotherapies with generally manageable side effects
- Supports personalized medicine approaches through genetic profiling
Cons
- Can cause significant side effects such as hypertension, diarrhea, and fatigue
- Not universally effective; response varies among patients
- Resistance to therapy can develop over time
- High cost of targeted therapies may limit access for some patients